Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine.


Journal Article (Letter)

Trimethoprim-sulfamethoxazole has been recommended as part of the standard package of care for people with HIV and AIDS in Africa. A similar antifolate combination, sulfadoxine-pyrimethamine, is now the first-line antimalarial drug in several of the African countries with the highest rates of HIV infection. We present evidence of Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine at the molecular level. The impact of trimethoprim-sulfamethoxazole on the efficacy of sulfadoxine-pyrimethamine needs to be assessed urgently, and alternative antimalarial treatment should be considered for people on trimethoprim-sulfamethoxazole prophylaxis.

Full Text

Cited Authors

  • Iyer, JK; Milhous, WK; Cortese, JF; Kublin, JG; Plowe, CV

Published Date

  • September 2001

Published In

Volume / Issue

  • 358 / 9287

Start / End Page

  • 1066 - 1067

PubMed ID

  • 11589941

Pubmed Central ID

  • 11589941

Electronic International Standard Serial Number (EISSN)

  • 1474-547X

International Standard Serial Number (ISSN)

  • 0140-6736

Digital Object Identifier (DOI)

  • 10.1016/s0140-6736(01)06201-8


  • eng